EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, X4 Pharmaceuticals's enterprise value is $153.74 Mil.
X4 Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, X4 Pharmaceuticals's EV-to-Revenue for today is .
The historical rank and industry rank for X4 Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
During the past 9 years, the highest EV-to-Revenue of X4 Pharmaceuticals was 53.25. The lowest was -8.65. And the median was -0.22.
XFOR's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.37 * Ranked among companies with meaningful EV-to-Revenue only.
The historical data trend for X4 Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of X4 Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, X4 Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
X4 Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where X4 Pharmaceuticals's EV-to-Revenue falls into.
X4 Pharmaceuticals's current Enterprise Value is $153.74 Mil.
X4 Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
X4 Pharmaceuticals's share price for today is $1.05.
X4 Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
X4 Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of X4 Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
X4 Pharmaceuticals (X4 Pharmaceuticals) Business Description
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XFOR has been successfully added to your 